[Proliferation and cytotoxicity of RetroNectin-activated cytokine-induced killer cells against cisplatin-resistant lung carcinoma cell].
To investigate the immunologic characteristics and cytotoxicity of the RetroNectin-activated cytokine-induced killer cells (CIK) against drug-resistant lung cancer cell lines DDP-A549 (DDP: Cisplatin). Peripheral blood mononuclear cells (PBMC) were collected from healthy donors and divided into two groups: group I and group II. Seeded samples of group I into culture flask precoated with RetroNectin and CD3MAb to induce the CIK cells while seeded the group II into culture flask precoated with CD3MAb. In both groups, IFN-gamma was put into the flask on the same day and then IL-2 on the second day. The proliferation of CIK cells was tested by cytometirc analysis. The cytotoxicity activity of CIK cells was determined by MTT assays. The phenotype changes of CIK cells were identified by flow cytometric analysis. Scanning electron microscope (SEM) and transmission electron microscope (TEM) were used to view the cytotoxicity against DDP-A549 of CIK cells and the changes of DDP-A549. The total CIK cells significantly increased by 524.77 fold in cell proliferation number due to the activation to CIK cells of RetroNectin. The expression rate of CD3+CD56+ cells was (31.40 +/- 1.91)%. The cytotoxicity of CIK cells showed statistically significance between DDP-A549 and the sensitive strains of parental generation A549 (P < 0.01). There was no significant difference of CIK cells' cytotoxicity between two groups when the effector: target ratio was fixed (P > 0.05). RetroNectin can significantly improve the proliferation activity of CIK cells. There was no evident influence to the cytotoxicity of CIK cells. CIK cells may be used as the immuotherapy to lung adenocarcinoma owing to its significant inhibition to the proliferation of DDP-A549.
Ren
Wei
W
Cancer Research Institute of Harbin Medical University, Harbin 150081, China.
Wang
Zhihua
Z
D000230:Adenocarcinoma / Q000276:immunology / Q000473:pathology; D002945:Cisplatin / Q000494:pharmacology; D055612:Cytokine-Induced Killer Cells / Q000166:cytology* / Q000276:immunology*; D003602:Cytotoxicity, Immunologic; D019008:Drug Resistance, Neoplasm; D005353:Fibronectins / Q000378:metabolism / Q000494:pharmacology*; D006801:Humans; D008175:Lung Neoplasms / Q000276:immunology / Q000473:pathology*; D011994:Recombinant Proteins / Q000494:pharmacology; D014407:Tumor Cells, Cultured
D005353:Fibronectins; D011994:Recombinant Proteins; D002945:Cisplatin